Mutations in the signal transducer and activator of transcription 3 (STAT3) and diagnostic guidelines for the Hyper-IgE Syndrome

Woellner, CristinaGertz, M. E.Schaffer, AlejandroLagos, MacarenaPerro, MarioGlocker, Erik-OliverPietrogrande, Maria CristinaCossu, FaustoMarin Franco, Jose LuisMatamoros, N.Pietrucha, BernardHeropolitanska-Pliszka, EdytaYeganch, M.Rezaei, NimaEspanol, TeresaEhl, StephanGennery, Andrew R.Abinun, MarioBreborowicz, AnnaNiehues, TimJunker, Anne K.Turvey, Stuart E.Plebani, AlessandroSanchez, Berta Erika LuisGarty, Ben ZionPignata, ClaudioCancrini, CaterinaLitzman, JiříSanal, ÖzdenBatimann, U.Bacchetta, RosaHsu, Amy P.Davis, Joie N.Hammarström, Lennart L.G.Davis, Edward GrahamEren, EfremArkwright, Peter D.Moilanen, Jukka S.Viemann, DorotheeKhan, SujoyMáródi, László D.R.Cant, Andrew JamesFreeman, Alexandra F.Puck, Jennifer M.Holland, Steven M.Grimbacher, Bodo2022-09-062022-09-062010-04Woellner, C. vd. (2010). "Mutations in the signal transducer and activator of transcription 3 (STAT3) and diagnostic guidelines for the Hyper-IgE Syndrome". Clinical and Experimental Immunology, 160(Supplement 1), 4-4.0009-91041365-2249https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878129/?report=readerhttp://hdl.handle.net/11452/28492Bu çalışma, 29-27 Kasım 2009 tarihleri arasında Bath[İngiltere]’da düzenlenen United Kingdom Primary Immunodeficiency Network Immunology Forum’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessImmunologyMutations in the signal transducer and activator of transcription 3 (STAT3) and diagnostic guidelines for the Hyper-IgE SyndromeMeeting Abstract00027680580001044160Supplement 1Immunology